Articles

CheckMate-577 clinical trial results show nivolumab adjuvant therapy increases disease-free survival over placebo in patients with gastroesophageal junction (GEJ) cancer or esophageal cancer. Read More ›

Second-line or later nivolumab monotherapy yields no clear evidence of efficacy advantage for patients with advanced esophageal cancer. Read More ›

Recently released positive findings from the LEAP-005 trial of lenvatinib plus pembrolizumab in the treatment of previously treated gastric cancer leads to cohort expansion. Read More ›

Results from the CheckMate-648 study demonstrate that nivolumab added to either ipilimumab or chemotherapy improves overall survival in patients with advanced esophageal squamous-cell carcinoma. Read More ›

DKN-01 plus tislelizumab and CAPOX combination demonstrates promising response rates and safety data in phase 2a study. Read More ›

Nivolumab combined with chemotherapy had improved survival outcomes and an acceptable safety profile in patients with advanced gastric/esophageal cancer, according to CheckMate-649 study results. Read More ›

In patients receiving treatment with CDK4/6 inhibitors, levels of neutralizing antibodies post-vaccination were similar to those in matched healthy controls. Read More ›

Although CDK4/6 inhibitors in the treatment of patients with hormone receptor–positive/HER2-negative advanced breast cancer improve progression-free survival, this therapeutic intervention is also associated with higher rates of adverse events. Read More ›

To ensure the correct use of healthcare services, it is critical to invest in training nursing professionals who must educate patients on the timely recognition and management of complications. Read More ›

Study shows no compromise in treatment safety or efficacy associated with dose reduction of ribociclib. Read More ›